Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest’s LABA/LAMA Delay Gives GSK A Lengthy Lead On The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

News that Forest/Almirall’s LABA/LAMA combination will be delayed due to a manufacturing issue means that GlaxoSmithKline’s Anoro Ellipta will continue to dominate the market as the sole fixed-dose combination available in the U.S.


Related Content

AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture
Almirall Eyes Top Specialty Dermatology Role After its AstraZeneca Deal
Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues
With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
GSK’s Big Push To Maintain Its Respiratory Reign
Forest COPD Combo Hits Roadblock En Route To NDA Filing
COPD Market Snapshot: New Products, Limited Differentiation
Novartis Once-Daily COPD Combo Safe, Effective And Ready For Filing – Everywhere But In The U.S.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts